The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling.
Frontiers in oncology
View this publicationFrontiers in oncology
View this publicationPublication categories: Top publication
Nature communications
View this publicationPublication categories: Top publication
Nucleic acids research
View this publicationCell reports
View this publicationHGG advances
View this publicationThe Journal of experimental medicine
View this publicationMethods in enzymology
View this publicationNature neuroscience
View this publicationInternational journal of molecular sciences
View this publicationBMC biology
View this publication